Clinical evaluation of a scintigraphic method for diagnosing inflammations/infections using indium-111-labeled nonspecific human IgG.
This study was undertaken as part of a Phase II study to assess the sensitivity and safety of 111In-DTPA-human IgG, an imaging agent for the detection of inflammations and/or infections. Forty patients with infection/inflammation on the basis of clinical findings, microbiologic results, and/or the basis of results from other imaging modalities were studied. For evaluation of sensitivity, whole-body images were obtained at 6-12 hr (early) and 20-28 hr (delayed) postinjection and occasionally at 48 hr. No adverse reactions were recorded in any of the 40 patients studied. Positive results were obtained in 37 of 37 evaluable subjects (100%). The test appears to be a promising method for the detection of inflammation and/or infection.
Serafini
A N
AN
University of Miami/Jackson Memorial Medical Center, Florida.
Garty
I
I
Vargas-Cuba
R
R
Friedman
A
A
Rauh
D A
DA
Neptune
M
M
Landress
L
L
Sfakianakis
G N
GN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D007239:Infections / Q000000981:diagnostic imaging*; D007249:Inflammation / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D004369:Pentetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity
C069971:DTPA-IgG complex; D007074:Immunoglobulin G; D004369:Pentetic Acid